Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma

被引：0
|
作者：
Mi Na Kim
Seung Min Lee
Jin Sung Kim
Seong Gyu Hwang
机构：
[1] CHA University School of Medicine,Division of Gastroenterology, Department of Internal Medicine, CHA Bundang Medical Center
[2] CHA University,Institute for Clinical Research, CHA Bundang Medical Center
[3] School of Medicine,undefined
[4] CMG Pharmaceutical CO.,undefined
[5] LTD,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词：
Hepatocellular carcinoma; PI3K/AKT/mTOR pathway; Sorafenib; Dual PI3K/mTOR inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：809 / 817
页数：8
相关论文
共 50 条
  • [21] Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib
    Lachenmayer, Anja
    Toffanin, Sara
    Cabellos, Laia
    Alsinet, Clara
    Hoshida, Yujin
    Villanueva, Augusto
    Minguez, Beatriz
    Tsai, Hung-Wen
    Ward, Stephen C.
    Thung, Swan
    Friedman, Scott L.
    Llovet, Josep M.
    JOURNAL OF HEPATOLOGY, 2012, 56 (06) : 1343 - 1350
  • [22] Preclinical activity of dual PI3K/mTOR inhibitor SPR965 in multiple myeloma
    Larsen, Jeremy T.
    Ramakrishnan, Vijay
    Haug, Jessica
    Kimlinger, Teresa
    Sen, Somdutta
    Mahajan, Dinesh
    Dugar, Sundeep
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    CANCER RESEARCH, 2015, 75
  • [23] PUMC-MB1 is a novel group 3 medulloblastoma preclinical model, sensitive to PI3K/mTOR dual inhibitor
    Wang, Shizun
    Zhang, Dan
    Wang, Jialin
    Peng, Xiaojiao
    Sun, Hailang
    Ji, Yuanqi
    Yang, Zhenli
    Bian, Xiaocui
    Hou, Yuhong
    Ge, Ming
    Liu, Yuqin
    JOURNAL OF NEURO-ONCOLOGY, 2024, 168 (01) : 139 - 149
  • [24] Apitolisib. Dual PI3K/mTOR inhibitor, Oncolytic
    de Lartigue, Jane
    DRUGS OF THE FUTURE, 2013, 38 (10) : 671 - 678
  • [25] Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines
    Masuda, Mitsuhiro
    Shimomura, Manami
    Kobayashi, Ken
    Kojima, Shuji
    Nakatsura, Tetsuya
    ONCOLOGY REPORTS, 2011, 26 (05) : 1273 - 1279
  • [26] Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
    Zhou, Qian
    Lui, Vivian W. Y.
    Yeo, Winnie
    FUTURE ONCOLOGY, 2011, 7 (10) : 1149 - 1167
  • [27] Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
    Sun, Eun Jin
    Wankell, Miriam
    Palamuthusingam, Pranavan
    McFarlane, Craig
    Hebbard, Lionel
    BIOMEDICINES, 2021, 9 (11)
  • [28] Anti-tumor Efficacy Profile of a Novel Dual PI3K/mTOR Inhibitor, DS-7423
    Hirota, Y.
    Sato, K.
    Hama, Y.
    Nagashima, Y.
    Watanabe, R.
    Suzuki, N.
    Sugimura, M.
    Shiose, Y.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 110 - 110
  • [29] GSK458 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in T Cell Lymphomas As a Single Agent and in Combination Therapy
    Gu, Juan
    Yang, Lianjuan
    Gaughan, Dennis C.
    He, Ling
    Shen, Weina
    Mavis, Cory
    Hernandez-Ilizaliturri, Francisco J.
    BLOOD, 2018, 132
  • [30] Antitumor efficacy of EGFR antibody necitumumab and dual PI3K/mTOR inhibitor (LY3023414) in preclinical tumor models
    Melchior, Maxine A.
    Guo, Xuemei
    Donoho, Gregory P.
    Iversen, Philip W.
    Doman, Thompson N.
    Brahmachary, Manisha
    Gong, Xueqian
    Hall, Gerald E.
    Manro, Jason R.
    Yao, Yung-mae M.
    Buchanan, Sean
    Smeal, Tod
    Kalos, Michael D.
    Novosiadly, Ruslan D.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
12345